Respiratory Drugs Market Size, Share & Industry Analysis, By Drug Class (Short-Acting Beta2-Agonists, Long-Acting Beta2-Agonists, Inhaled Corticosteroids, Anticholinergics, Antihistamines) By Disease Type (Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease, Pleural Effusion), By Route of Administration (Inhalation, Enteral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Respiratory drugs are the medications used for the treatment of various respiratory diseases. With the growing population, adoption of sedentary lifestyle, and rising incidences of pulmonary disease globally will increase the demand for the effective respiratory drugs. According to World Health Organization (WHO) it was estimated that 251 million cases of chronic obstructive pulmonary disease (COPD) were registered.
Frequent respiratory infections, and increased exposure to indoor & outdoor air pollution and chemicals occupational dust, and growing smoking population globally are likely to boost the demand for innovative drugs for treatment of respiratory diseases. Presence of strong pipeline drugs is anticipated to fuel the respiratory drugs market growth during the forecast period
To gain extensive insights into the market, Request for Customization
Growing adoption of innovative drugs for the treatment of various respiratory diseases and increase in the investments in R&D activities by major key players are likely to drive the respiratory drugs market growth during the forecast period. Additionally, growing patient population and growing demand for drugs for the treatment of respiratory diseases are expected to augment the respiratory drugs market growth during the forecast period.
However, stringent regulatory scenario for the approval of many drugs for the treatment of respiratory diseases is likely to hinder the respiratory drugs market growth during the forecast period.
Key Players Covered
Some of the major companies that are present in the global respiratory drugs market report include VAPOTHERM, AptarGroup, Inc., Drägerwerk AG & CO., Allied Healthcare, Cardinal Health, NSPIRE HEALTH INC. oninklijke Philips N.V., and others
Segmentation
ATTRIBUTE | DETAILS |
By Drug Class |
|
By Disease Type |
|
By Route of Administration |
|
By Distribution Channel |
|
By Geography |
|
In terms of drug class, combination drugs segment is anticipated to hold the respiratory drugs market share during the forecast period as they are more effective that other drugs and are easily affordable due to their low cost.
Key Insights
- Overview of pipeline drugs for respiratory disease treatment
- The Regulatory scenario for key countries
- Key Industry Developments –mergers, partnerships, and acquisitions
Regional Analysis
The global respiratory drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Asia and Africa. North America is anticipated to hold the largest respiratory drugs market share during the forecast period owing to the presence of prominent key market players in U.S. and growing strategic partnerships among these key players in launching of new products. In Europe rising awareness about innovative respiratory drugs are anticipated to drive the respiratory drugs market growth during the forecast period. Growing patient population and penetration of generic drugs for the treatment of various respiratory drugs are likely to boost the respiratory drugs market growth in Asia Pacific region. In Middle East & Africa the growing unmet need for the effective drugs for the treatment of respiratory diseases is anticipated to drive the respiratory devices market growth during the forecast period.
Key Industry Developments
- In March 2019, Circassia. Received FDA approval for the use of Tudoorza for the maintenance& treatment of chronic obstructive pulmonary disease (COPD)
- In November 2018, Theravance Biopharma and Mylan N.V. received approval from FDA for New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
